Akili Interactive
Akili Interactive develops prescription digital therapeutics delivered through video games. Its products include EndeavorRx for children ages 8 to 17 and EndeavorOTC for adults, both FDA-authorized treatments for ADHD designed to improve attention function through adaptive gameplay.
PaidVerified
What is Akili Interactive?
Akili's digital medicines use a proprietary Selective Stimulus Management Engine to present sensory stimuli and motor challenges that target neural systems involved in attention. The games adapt difficulty in real time based on player performance, ensuring personalized treatment. EndeavorRx is for children, while EndeavorOTC is available on app stores for adults. Clinical studies demonstrate measurable improvements in attention control.
Key features
- FDA-authorized prescription video game for ADHD
- Adaptive difficulty that personalizes treatment in real time
- Selective Stimulus Management Engine targeting attention pathways
- Parent progress monitoring via companion app
- Clinical validation across five studies with 600+ participants
- Game-based digital therapeutics
- FDA-authorized treatments
- Adaptive gameplay
- Companion app for monitoring
Use cases
- A child with ADHD plays EndeavorRx for 25 minutes daily, five days a week, as part of a prescribed therapeutic program to improve attention function.
- A parent monitors their child treatment progress through the companion app, tracking daily engagement and observing improvements in attention over time.
- A clinician prescribes EndeavorRx as a complementary treatment alongside behavioral therapy and medication for a comprehensive ADHD management plan.
- ADHD treatment for children
- ADHD treatment for adults
- Non-pharmacological ADHD therapy
Who is it for
- Children
- adults with ADHD
- parents seeking non-pharmacological treatment options
- clinicians prescribing multimodal ADHD therapy
- families affected by stimulant medication shortages